Everest Medicines Limited (HKEX: 1952.HK) has announced the launch of an Investigator-Initiated Clinical Trial (IIT) for its innovative personalized mRNA cancer vaccine, EVM16. The trial, designated EVM16CX01, is set to take place at Peking University Cancer Hospital and Fudan University’s Cancer Hospital. This groundbreaking study will be the first-in-human (FIH) trial for EVM16, designed to […]
Everest Medicines, a China-based biopharmaceutical company, has commenced operations at its mRNA vaccine production plant in Jiashan, Zhejiang Province, thereby becoming a fully-integrated biopharma. With the first phase going live, Everest Medicines now owns complete pharmaceutical and vaccine value chain from discovery, clinical development, manufacturing, and commercialization. The first phase of the vaccine manufacturing facility […]
